- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Reports First Quarter 2024 Results
- Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
- Royalty Pharma Declares Second Quarter 2024 Dividend
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
- Royalty Pharma Reports Q4 and Full Year 2023 Results
- Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
More ▼
Key statistics
On Friday, Royalty Pharma PLC (RPRX:NSQ) closed at 27.41, 5.75% above its 52-week low of 25.92, set on Sep 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.50 |
---|---|
High | 27.49 |
Low | 26.45 |
Bid | 27.41 |
Offer | 27.50 |
Previous close | 26.39 |
Average volume | 3.07m |
---|---|
Shares outstanding | 597.44m |
Free float | 385.62m |
P/E (TTM) | 15.38 |
Market cap | 16.38bn USD |
EPS (TTM) | 1.78 USD |
Annual div (ADY) | 0.84 USD |
---|---|
Annual div yield (ADY) | 3.18% |
Div ex-date | May 16 2024 |
Div pay-date | Jun 14 2024 |
Data delayed at least 15 minutes, as of May 31 2024 21:15 BST.
More ▼